ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Trovagene Completes Dosing of Patients Treated with Onvansertib, Decitabine in AML Trial
September 28, 2018Trovagene announced completion of the second dosing cohort of Onvansertib, its first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) Inhibitor, in combination with standard-of-care decitabine, in its Phase 1b/2 clinical trial in -
Tolero Pharmaceuticals collaborates with AbbVie for AML trial
August 21, 2018Under the terms of the agreement, Tolero and AbbVie will equally share all development expenses. Tolero will retain full commercial rights for alvocidib and AbbVie will retain full commercial rights for venetoclax.
Pharma Sources Insight January 2025
